Astellas' New Data on Cresemba for Invasive Mucormycosis - Analyst Blog
Astellas Pharma, Inc. ( ALPMY ) announced the presentation of new data on Cresemba (isavuconazole) from an open-label, multi-center phase III study (VITAL) for invasive mucormycosis (also known as zygomycosis) in immunocompromised patients.
NASDAQ - Thu, 09 Oct 2014 13:37



news
There are more than 10,000 diseases on the planet, asthma to zygomycosis. Geoffrey Siwo wants to cure all of them. And the 35-year-old computational biologist believes he can. Or, rather, that we can, if we can disrupt drug discovery. It's worth ...
USA TODAY - Thu, 02 Oct 2014 07:11

Isavuconazole demonstrates successful outcomes in treatment of mucormycosis
The U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). In accordance with the FDA ...
News-Medical.net - Wed, 08 Oct 2014 06:18

Positive new findings for Astellas' isavuconazole in mucormycosis
The Pharma Letter - Wed, 08 Oct 2014 08:16

New antifungal is as effective as existing drugs and with fewer adverse events
A newly developed antifungal, isavuconazole, is as effective against invasive mold disease in cancer patients as the existing drug, voriconazole. In addition, isavuconazole has fewer adverse effects. This data from a phase 3 clinical trial was ...
Oncology Nurse Advisor - Fri, 03 Oct 2014 06:07

Basilea berichtet über Präsentation weiterer Subgruppen- und ...
Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. International Journal of Infectious Diseases 2010 (14S), e100-e103. 6 J. Wingard. Zygomycosis: Epidemiology and treatment options. Proceedings 2006 (6) ...
BörseGo.de - Wed, 08 Oct 2014 10:37


1  


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014